



APOE genotyping

An important clue from the DNA



Clinical studies show:

Carriers of the **APOE ε4** allele are at **increased risk of** potentially life-threatening side effects (**ARIA**, amyloid-related imaging abnormalities) in the form of brain oedema/bleeding under anti-beta-amyloid antibody treatment of Alzheimer's disease.¹



Recommendation from literature:

APOE genotyping prior to anti-beta-amyloid antibody treatment to assess the individual ARIA risk²

1. Filippi M, et al. Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review. *JAMA Neurol* 79(3):291–304 (2022).
2. Cummings J, et al. Lecanemab: Appropriate Use Recommendations. *J Prev Alzheimers Dis* 10(3):362-377 (2023).

EURORealTime APOE

- Real-time PCR-based multiplex test for precise typing of APOE alleles ε2, ε3 and ε4
- Compatible with various real-time PCR cyclers
- Automated output of results using the EURORealTime Analysis software

Regulatory status of the products must be verified for the user's individual jurisdiction.
Please contact your country representative for product availability and information.

TOGETHER AT THE PULSE OF NEUROLOGY

neurodiagnostics@euroimmun.de

